|
|
Volumn 50, Issue 9, 2010, Pages 986-1000
|
|
Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
APIXABAN;
BENZAMIDE DERIVATIVE;
BETRIXABAN;
BLOOD CLOTTING FACTOR 10A;
LOW MOLECULAR WEIGHT HEPARIN;
MORPHOLINE DERIVATIVE;
PYRAZOLE DERIVATIVE;
PYRIDINE DERIVATIVE;
PYRIDONE DERIVATIVE;
RIVAROXABAN;
THIOPHENE DERIVATIVE;
WARFARIN;
ARTICLE;
BLOOD CLOTTING DISORDER;
CLINICAL TRIAL (TOPIC);
DRUG ANTAGONISM;
HEART ATRIUM FIBRILLATION;
HUMAN;
ORAL DRUG ADMINISTRATION;
PATHOPHYSIOLOGY;
STROKE;
THROMBOEMBOLISM;
ADMINISTRATION, ORAL;
ANTICOAGULANTS;
ATRIAL FIBRILLATION;
BENZAMIDES;
BLOOD COAGULATION DISORDERS;
CLINICAL TRIALS AS TOPIC;
FACTOR XA;
HEPARIN, LOW-MOLECULAR-WEIGHT;
HUMANS;
MORPHOLINES;
PYRAZOLES;
PYRIDINES;
PYRIDONES;
STROKE;
THIOPHENES;
THROMBOEMBOLISM;
WARFARIN;
|
|
EID: 78650932475
PISSN: None
EISSN: 15524604
Source Type: Journal
DOI: 10.1177/0091270009355814 Document Type: Article |
|
Times cited : (10)
|
|
References (0)
|
